Biopharmaceutical company Swedish Orphan Biovitrum AB (Sobi) (STO:SOBI) reported on Tuesday that the first patient has been dosed in the phase 3, open-label, interventional XTEND-Kids study of efanesoctocog alfa (BIVV001) in children with severe haemophilia A.
Efanesoctocog alfa is being developed and will be commercialised in partnership with Sanofi (EPA:SAN).
In the non-randomised, single-arm study, participants will receive a weekly prophylactic dose of efanesoctocog alfa for 52 weeks. The trial will evaluate efficacy, safety and pharmacokinetics in approximately 65 previously treated patients aged 12 years and under.
Efanesoctocog alfa was granted Fast Track designation by the US Food and Drug Administration (FDA) in February 2021. It was also granted Orphan Drug designation by the US FDA in August 2017 and the European Commission in June 2019.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study